Therapeutic vaccines in renal cell carcinoma

Therapy

Volumn 8, Issue 4, 2011, Pages 369-377

  Schwaab, Thomas ^a   Ernstoff, Marc S ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NONE

Author keywords

dendritic cells; immune therapy; renal cell cancer; T cells; tumor vaccine

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA INTERFERON; ALPHA2A INTERFERON; CANCER VACCINE; CARBONATE DEHYDRATASE IX; DENDRITIC CELL VACCINE; GIRENTUXIMAB; HLA ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2; MUCIN 1; NY ESO 1 ANTIGEN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DENDRITIC CELL SARCOMA; HLA SYSTEM; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

EID: 79961074467     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.40     Document Type: Review

References (55)

1. Hoption Cann SA, van Netten JP, van Netten C, Glover DW. Spontaneous regression: a hidden treasure buried in time. Med. Hypotheses 58(2), 115-119 (2002). (Pubitemid 34174418)
2. Coley WB. The treatment of malignant tumors by repeated inocolulations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. Volume 5, Paris, 487-511 (1893).
3. Neidhart JA, Murphy SG, Hennick LA, Wise HA. Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer 46(5), 1128-1134 (1980). (Pubitemid 10043479)
4. McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 32(1), 62-66 (1990).
5. Sahasrabudhe DM, deKernion JB, Pontes JE et al. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J. Biol. Response Mod. 5(6), 581-594 (1986). (Pubitemid 17224169)
6. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196(12), 1627-1638 (2002). (Pubitemid 36026474)
7. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194(6), 769-779 (2001). (Pubitemid 32983013)
8. Barth RJ Jr, Fisher DA, Wallace PK et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin. Cancer Res. 16(22), 5548-5556 (2010).
9. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4(10), 762-774 (2004). (Pubitemid 39336293)
10. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-a-based immunotherapy compared with interferon a alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286), 966-970 (2001). (Pubitemid 32913522)
11. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon a-2b compared with interferon a-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345(23), 1655-1659 (2001). (Pubitemid 33126820)
12. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363(9409), 594-599 (2004). (Pubitemid 38264176)
13. Shablak A, Hawkins RE, Rothwell DG, Elkord E. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin. Cancer Res. 15(21), 6503-6510 (2009).
14. Bauer S, Oosterwijk-Wakka JC, Adrian N et al. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int. J. Cancer 125(1), 115-123 (2009).
15. Kim HL, Sun X, Subjeck JR, Wang XY. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol. Immunother. 56(7), 1097-1105 (2007). (Pubitemid 46675302)
16. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J. Immunother. 30(1), 116-122 (2007). (Pubitemid 46052210)
17. Siebels M, Rohrmann K, Oberneder R et al. A clinical Phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-a-2a in metastatic renal cell carcinoma patients. World J. Urol. 29(1), 121-126 (2011).
18. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22-32 (2002). (Pubitemid 35398862)
19. Tsuji T, Matsuzaki J, Kelly MP et al. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J. Immunol. 186(2), 1218-1227 (2011).
20. Amata RJ, Shingler W, Naylor S et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a Phase II trial. Clin. Cancer Res. 14(22), 7504-7510 (2008).
21. Kaufman HL, Taback B, Sherman W et al. Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J. Transl. Med.7, 2 (2009).
22. Hawkins RE, Macdermott C, Shablak A et al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the antigen 4T4 (TroVax) given alongside interferon-a. J. Immunother. 32(4), 424-429 (2009).
23. Amato RJ, Shingler W, Goonewardena M et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-a (IFN-a): a Phase 2 trial. J. Immunother. 32(7), 765-772 (2009).
24. Okamura K, Koike H, Sekine Y, Matsui H, Suzuki K. Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer. Cancer Epidemiol. 33(2), 137-141 (2009).
25. Ciesielski MJ, Ahluwalia MS, Munich SA et al. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol. Immunother. 59(8), 1211-1221 (2010).
26. Marten A, Sievers E, Albers P et al. Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Ger. Med. Sci. 4, Doc02 (2006).
27. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun. 7, 21 (2007).
28. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 61(8), 3388-3393 (2001). (Pubitemid 32695030)
29. Schwaab T, Heaney JA, Schned AR et al. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon g and human recombinant interferon a2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J. Urol. 163(4), 1322-1327 (2000). (Pubitemid 30169433)
30. Schwaab T, Schwarzer A, Wolf B et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (interleukin 2) and IFN-{a}2a therapy in metastatic renal cell carcinoma patients. Clin. Cancer Res. 15(15), 4986-4992 (2009).
31. Van Poppel H, Joniau S, Van Gool SW. Vaccine therapy in patients with renal cell carcinoma. Eur. Urol. 55(6), 1333-1342 (2009).
32. May M, Brookman-May S, Hoschke B et al. Ten-year survoival analysis for renal carcinoma patients treated with an autologous tumor lysate vaccine in an adjuvant setting. Cancer Immunol. Immunother. 59(5), 687-695 (2010).
33. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099-1105 (2010).
34. Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59(5), 663-674 (2010).
35. Schwaab T, Tretter CP, Gibson JJ et al. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J. Urol. 171(3), 1036-1042 (2004). (Pubitemid 38327521)
36. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ Jr. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res. 61(2), 641-646 (2001). (Pubitemid 32128627)
37. Bedrosian I, Mick R, Xu S et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J. Clin. Oncol. 21(20), 3826-3835 (2003). (Pubitemid 46606238)
38. Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-k B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. J. Immunol. 171(8), 4121-4130 (2003). (Pubitemid 37238688)
39. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl Acad. Sci. USA 95(16), 9482-9487 (1998). (Pubitemid 28506257)
40. Schwaab T, Schned AR, Heaney JA et al. In vivo description of dendritic cells in human renal cell carcinoma. J. Urol. 162(2), 567-573 (1999). (Pubitemid 29434398)
41. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3(3), 483-490 (1997). (Pubitemid 27158075)
42. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4(3), 585-593 (1998). (Pubitemid 28193556)
43. Lou Y, Wang G, Lizee G et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 64(18), 6783-6790 (2004). (Pubitemid 39297942)
44. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21(21), 4016-4026 (2003). (Pubitemid 46606217)
45. Giermasz AS, Urban JA, Nakamura Y et al. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol. Immunother. 58(8), 1329-1336 (2009).
46. Lapenta C, Santini SM, Logozzi M et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-a. J. Exp. Med. 198(2), 361-367 (2003). (Pubitemid 36987861)
47. Dubsky P, Saito H, Leogier M et al. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur. J. Immunol. 37(6), 1678-1690 (2007). (Pubitemid 46939501)
48. Eggermont AM, Suciu S, Rutkowski P. Randomized Phase III trial comparing postoperative adjuvant ganglioside GM@-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961. J. Clin. Oncol. 28(15S) (2010) (Abstract 8505).
49. Morton DL, Mossillo N, Thompson JF. An international, randomized, Phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites 2007. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(Suppl. 18) (2007) (Abstract 8508).
50. McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 115(10 Suppl.), 2298-2305 (2009).
51. Anderson PO, Sundstedt A, Yazici Z et al. IL-2 overcomes the unresponsiveness but fails to reverse the regulatory function of antigen-induced T regulatory cells. J. Immunol. 174(1), 310-319 (2005). (Pubitemid 40007418)
52. Rao RR, Li Q, Shrikant PA. Fine-tuning CD8+ T cell functional responses: mTOR acts as a rheostat for regulating CD8+ T cell proliferation, survival and differentiation? Cell Cycle 9(15), 2996-3001 (2010).
53. Jensen HK, Donskov F, Norsmark M et al. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment for metastatic renal cell carcinoma. Clin. Cancer Res. 15,1052-1058 (2009).
54. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175(11), 7746-7754 (2005). (Pubitemid 41713475)
55. Laschos KA, Papazisis KT, Kontovinis LF et al. Targeted treatment for metastatic renal cell carcinoma and immune regulation. J. BUON 15(2), 235-240 (2010).